ArticleEMBO reports2018

Setbacks and promises for drugs against Alzheimer's disease: As pharmaceutical companies are retreating from drug development for Alzheimer's, new approaches are being tested in academia and biotech companies.

Andrea RinaldiPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.